Open AccessDrug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
Author(s) -
Prasad Thota,
Anusha Thota,
Bikash Medhi,
Shabir Sidhu,
Pramod Kumar,
V Kalai Selvan,
Gyanendra Singh
Publication year - 2018
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/picr.picr_29_17
Subject(s) - pharmacovigilance , medicine , christian ministry , patient safety , postmarketing surveillance , medical emergency , government (linguistics) , chemical safety , drug , adverse drug reaction , pharmacology , family medicine , health care , adverse effect , risk analysis (engineering) , philosophy , linguistics , theology , economics , economic growth
The National Coordination Centre-Pharmacovigilance Programme of India (NCC-PvPI), Indian Pharmacopoeia Commission works under the aegis of Ministry of Health and Family Welfare, Government of India. It promotes patient safety in India and also supports postmarketing surveillance programs. Currently, almost hundred thousand case reports are submitted to NCC-PvPI each year through its 250 ADR Monitoring Centers (AMCs) located across India, and India is the one of the top ten contributor countries under WHO-Uppsala Monitoring Centre since 2012 and start issuing drug safety alerts from March 2016.